ACCENT I Study Group. Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial, Lancet, 2002. ,
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease, New England Journal of Medicine, vol.350, issue.9, pp.876-85, 2004. ,
DOI : 10.1056/NEJMoa030815
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005. ,
DOI : 10.1056/NEJMoa050516
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-53, 2008. ,
DOI : 10.1016/j.cgh.2008.03.014
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease, Gastroenterology, 2005. ,
Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study, Gastroenterology, vol.135, issue.5, pp.1493-1499, 2008. ,
DOI : 10.1053/j.gastro.2008.07.069
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review, The American Journal of Gastroenterology, vol.118, issue.3, pp.760-767, 2009. ,
DOI : 10.1038/ajg.2008.88
The duration of effect of infliximab maintenance treatment in paediatric Crohn???s disease is limited, Alimentary Pharmacology & Therapeutics, vol.38, issue.2, pp.243-50, 2011. ,
DOI : 10.1111/j.1365-2036.2010.04507.x
Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease : a population-based study, Inflamm Bowel Dis, 2011. ,
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease, Journal of Crohn's and Colitis, vol.7, issue.5, pp.369-76 ,
DOI : 10.1016/j.crohns.2012.03.006
Long-term outcome of maintenance infliximab therapy in children with Crohn??s disease, Inflammatory Bowel Diseases, vol.15, issue.6, pp.816-838, 2009. ,
DOI : 10.1002/ibd.20845
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis : results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum, 2002. ,
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.601-609, 2003. ,
DOI : 10.1056/NEJMoa020888
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-54, 2006. ,
DOI : 10.1016/j.cgh.2006.06.025
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010. ,
DOI : 10.1136/gut.2009.183095
Serum infliximab concentrations in pediatric inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.107, issue.1, pp.35-41 ,
DOI : 10.1056/NEJMoa020888
Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.20, issue.10, pp.1708-1721, 2014. ,
DOI : 10.1097/MIB.0000000000000137
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease, Gastroenterology, vol.148, issue.7, pp.1320-1329, 2015. ,
DOI : 10.1053/j.gastro.2015.02.031
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3791, 2006. ,
DOI : 10.1002/art.22214
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies, Scandinavian Journal of Gastroenterology, vol.30, issue.5, pp.774-81, 2009. ,
DOI : 10.1053/j.gastro.2006.11.041
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial, Gastroenterology, vol.124, issue.4, 2003. ,
DOI : 10.1053/gast.2003.50145
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, vol.56, issue.9, 2007. ,
DOI : 10.1136/gut.2006.099978
Rémicade® Annales de Dermatologie et de Vénéréologie, pp.978-981, 2007. ,
American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21???23, 2006, Gastroenterology, vol.133, issue.1, pp.312-351, 2006. ,
DOI : 10.1053/j.gastro.2007.05.006
Adverse effects of biologics used for treating IBD, Best Practice & Research Clinical Gastroenterology, vol.24, issue.2, pp.167-82, 2010. ,
DOI : 10.1016/j.bpg.2010.01.002
Serum sickness, encephalitis and other complications of anti-cytokine therapy, Best Practice & Research Clinical Gastroenterology, vol.23, issue.1, pp.101-113, 2009. ,
DOI : 10.1016/j.bpg.2008.12.005
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal, Alimentary Pharmacology & Therapeutics, vol.9, issue.Suppl. 1, 2015. ,
DOI : 10.1111/apt.13268
Could therapeutic drug monitoring of anti-TNF-? be useful to consider a de-escalation of treatment? Expert Opin Biol Ther, pp.1-3, 2015. ,
Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.18, issue.2, pp.349-58, 2012. ,
DOI : 10.1002/ibd.21831
Evaluation of the Pediatric Crohn Disease Activity Index: A Prospective Multicenter Experience, Journal of Pediatric Gastroenterology and Nutrition, vol.41, issue.4, pp.416-421, 2005. ,
DOI : 10.1097/01.mpg.0000183350.46795.42
Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study, Gastroenterology, vol.133, issue.2, 2007. ,
DOI : 10.1053/j.gastro.2007.05.029
Anti-TNF therapy for paediatric IBD: the Scottish national experience, Archives of Disease in Childhood, vol.7, issue.(Suppl A), pp.399-405, 2015. ,
DOI : 10.1136/archdischild-2013-305812
The effect of dose escalation on trough levels in patients who lost response to infliximab, Gut, vol.59, issue.3, p.81, 2010. ,
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis, Gastroenterology, vol.147, issue.6, p.2014 ,
DOI : 10.1053/j.gastro.2014.08.035
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial, Gut, vol.362, issue.(Suppl 1), pp.1721-1728, 2014. ,
DOI : 10.1136/gutjnl-2012-304094
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis, vol.7, issue.9, pp.736-779, 2013. ,
DOI : 10.1016/j.crohns.2012.10.019
Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.13, issue.3, pp.514-521 ,
DOI : 10.1016/j.cgh.2014.07.027
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease, Gut, vol.9, issue.10, p.2015 ,
DOI : 10.1136/gutjnl-2014-307883
O-003???Relationship Between Vedolizumab Pharmacokinetics and Endoscopic Outcomes of Patients With Ulcerative Colitis, Inflammatory Bowel Diseases, vol.20, issue.1, pp.1-6, 2014. ,
DOI : 10.1097/01.MIB.0000456699.04243.9e
The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.132, issue.Suppl. 1, 2008. ,
DOI : 10.1111/j.1365-2036.2008.03734.x
Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBD, Inflammatory Bowel Diseases, vol.21, issue.2, pp.307-321, 2015. ,
DOI : 10.1097/MIB.0000000000000284
Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center, Journal of Pediatric Gastroenterology and Nutrition, vol.58, issue.5, pp.582-589, 2014. ,
DOI : 10.1097/MPG.0000000000000276
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.20, issue.12, pp.2247-59, 2014. ,
DOI : 10.1097/MIB.0000000000000212
Skin reactions during anti-TNF? therapy for pediatric inflammatory bowel disease : a 2-year prospective study, Inflamm Bowel Dis, 2014. ,
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.10, pp.769-79, 2013. ,
DOI : 10.1016/j.crohns.2013.01.009
Infliximab-Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With IL-23 Receptor Polymorphisms, Journal of Pediatric Gastroenterology and Nutrition, vol.56, issue.5, pp.512-520, 2013. ,
DOI : 10.1097/MPG.0b013e31828390ba
Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterized by interferon-gammaexpressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment, Gut, vol.63, issue.4, pp.2014567-77 ,
Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD, Inflammatory Bowel Diseases, vol.20, issue.10, pp.1714-1735, 2014. ,
DOI : 10.1097/MIB.0000000000000138
A New Pediatric Protocol for Rapid Desensitization to Monoclonal Antibodies, International Archives of Allergy and Immunology, vol.165, issue.3, pp.214-222, 2014. ,
DOI : 10.1159/000369299